News
Latest news
Cancer drug developer CG Oncology valued at $1.75B in strong IPO debut

Reuters

January 25 2024
Synnovation Therapeutics Launches with $102M Series A Funding

Businesswire

January 24 2024
CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology

December 05 2023
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

CG Oncology

November 30 2023
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Arrivent Biopharma

October 30 2023
Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC

Arrivent Biopharma

September 10 2023

Get In Touch

Contact Us